Asalyxa is focused on the rapid development of a revolutionary neutrophil-targeting drug platform.
The versatility of Asalyxa’s proprietary platform allows for the direct delivery of microparticles into neutrophils, making the platform ideal for a variety of diseases where treatments are limited or do not exist.
Asalyxa is committed to developing neutrophil targeting treatments for diseases with a high unmet medical need, allowing today’s patients to enjoy a healthier tomorrow.
The versatility of Asalyxa’s proprietary platform allows for the direct delivery of microparticles into neutrophils, making the platform ideal for a variety of diseases where treatments are limited or do not exist.
Asalyxa is committed to developing neutrophil targeting treatments for diseases with a high unmet medical need, allowing today’s patients to enjoy a healthier tomorrow.
Location: United States, Michigan, Southfield
Employees: 11-50
Total raised: $2M
Founded date: 2020
Investors 5
| Date | Name | Website |
| - | Michigan R... | michiganri... |
| - | LoftyInc C... | loftyinc.v... |
| - | LoftyInc C... | loftyincca... |
| - | ID Venture... | idventures... |
| - | Grand Ange... | michiganca... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.02.2021 | Seed | $2M | - |
Mentions in press and media 1
| Date | Title | Description |
| 23.02.2021 | Asalyxa Bio Closes Over $2M Seed Financing | Asalyxa Bio, Inc., an Ann Arbor, Mich.-based biopharmaceutical company developing nano-engineered, immune cell-targeted therapeutics, closed a seed financing round totaling more than $2m. The round was led by Research Bridge Partners, co-le... |